BRIEF-Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa
April 26, 2018 at 08:25 AM EDT
* KRYSTAL BIOTECH ANNOUNCES FDA CLEARANCE OF IND ON KB103 TO BEGIN ENROLLING PATIENTS FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA
